Document Type
Poster
Publication Date
Fall 2021
Abstract
2-[(p-Chlorophenyl)hydroxymethyl]-1-[(methylamino)hexyl]cyclohexanol is a drug produced by hexyl amine and an epoxide through an aldol epoxidation reaction. Motifs of β-amino alcohols and nonpolar R groups in organic compounds have been found to have cytotoxic properties. Past studies in Dr. Hansen’s lab has shown that this hexylamine derivative has similar LC50 values to other antitumor agents. They also found that the drug was cytotoxic to HL-60 cancer cells. No other cell lines have been tested with this drug. Our study investigates the effect of our compound on varying cell lines to further determine its anticancer properties. Mouse NIH/3T3, Human HEK293, and Human SK-MEL-28 cell lines were cultured and plated into 96-well plates. Varying concentrations of the hexylamine derivative were administered and incubated for 48 hours. MTT assays detected the levels of cell viability. Results showed a significant decrease in HEK293 cells at a 30 μM concentration of our drug. The mouse and cancer cell lines did not produce significant results after statistical ANOVA tests. Future directions include further validation of the current results as well as research on the mechanisms by which this drug causes decreased cell viability. This research includes LDH and wound healing assays in addition to determining which proteins are down- and up-regulated in the process. Our study has found that the compound reduces human embryonic cell viability but does not significantly affect mouse cells or human melanoma cells. Further research is required to determine the methods of the drug and its potential in tumor treatment.
Recommended Citation
DeLancey, Rachel; Deju, Bamlak; Hansen, Jeff PhD; and Chopra, Nipun PhD, "Effect of a Hexylamine Derivative on Cancer Cell Viability" (2021). Annual Student Research Poster Session. 71, Scholarly and Creative Work from DePauw University.
https://scholarship.depauw.edu/srfposters/71
Comments
We would like to thank DePauw Chemistry Department for providing the hexylamine drug, Henning Schneider and Wendy Tomamichel for providing materials, and the Science Research Fellows (SRF) program for providing funding.